



BASL Immune SIG Update 2026 Meeting

Venue: Austin Court, 80 Cambridge Street, Birmingham, B1 2NP
22nd January 2026

Programme

09:30 – 10:00	Registration and coffee
10:00 – 10:05	Chair's Introduction and Welcome - Dr Palak Trivedi, UHB
10:05 – 10:30	State-of-the Art: Management of IgG4-related hepatopancreatobiliary disease in 2026 - Dr Emma Culver, Oxford
10:30 – 10:55	Transition of care from paediatric to adult hepatology practice - Dr Jeremy Shanika Nayagam – Kings College London (on behalf of Dr Deepak Joshi)
10:55 – 11:20	Learnings from the national genetic cholestatic disease MDT - Dr Jeremy Shanika Nayagam – Kings College London
11.20 – 11.35	Coffee and Exhibition
11:35 - 12.00	The EMPHATIC programme: liver transplantation for PSC and cholangiocarcinoma in the UK - Dr James Ferguson – UHB - Dr Douglas Thorburn – Royal Free London
12:00 – 12:25	UK-PSC update: from clinical trials to practice guidelines - Dr Palak Trivedi - UHB
12:25 – 12:50	Current landscape of the second-line therapies for PBC; where does the UK stand? - Dr Palak Trivedi, UHB
13:00 – 14:00	Lunch and Exhibition
14:00 – 14:25	UK-PBC: from clinical guidelines to real-world studies in PBC - Dr George Mells - Cambridge

14:25 – 14:50	Current status of the UK-PBC audit and implementation of the PBC care bundle - TBC
14:50 – 15:15	The UK-AIH audit and UK-AIH guidelines - Prof Dermot Gleeson - Sheffield
15:15 – 15:25	Comfort break
15:25 – 15:50	Implementation of the UK-AIH bundle - Dr Jessica Dyson - Newcastle
15:50 – 16:15	Contemporary clinical trial activity in AIH - Dr Emma Culver, Oxford
16:15 – 16:30	Review of the meeting and close - Dr Palak Trivedi, UHB

Sponsors

BASL would like to thank the following pharmaceutical companies who provided funding for this meeting.



BASL can confirm the sponsors for the event have had no influence over, or input into the content of the materials used at this meeting including the programme and selection of speakers.

For queries, please contact kim@basl.org.uk Tel. 01543 442154